Thus, genetic and/or pharmacologic interventions aimed at inhibiting Cdc20-APC/C-securin signaling may be a valid strategy to either enhance cancer cell death induced by chemotherapeutic drugs or limit undesired side effects caused by chemotherapy in NSCLC. This evidence concerns the gene APC and non-small cell lung carcinoma.